SCHEMBL20893408

SCHEMBL20893408

CCOC(=O)C#Cc1cc(OCC)cc(OCC)c1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
NPC1 O15118 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
PARP10 Q53GL7 1/20 0.39
NQO1 P15559 1/20 0.38
GAA P10253 1/20 0.37
PTGS2 P35354 1/20 0.37
LTA4H P09960 1/20 0.37
LMNA P02545 2/20 0.37
PLK1 P53350 1/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6553345 0.87 CYP3A4 (0.46) ALDH1A1NPC1L3MBTL1POLBMEN1
SCHEMBL11544791 0.85 ALDH1A1 (0.53) ALDH1A1NPC1L3MBTL1PARP10NQO1
SCHEMBL852779 0.83 ALDH1A1 (0.39) ALDH1A1KMT2A
SCHEMBL6553332 0.81 FFAR1 (0.41) LMNAMEN1CYP1A2KMT2ATDP1
SCHEMBL853115 0.78 GRM5 (0.38) ALDH1A1GAALMNAMEN1CYP1A2
SCHEMBL6553406 0.78 GPR35 (0.40) ALDH1A1LMNAMEN1CYP1A2KMT2A
SCHEMBL853694 0.78 CNR2 (0.39) L3MBTL1POLBCYP1A2MAPK1
SCHEMBL9935172 0.76 CA12 (0.50) ALDH1A1NPC1GAALTA4HLMNA
SCHEMBL853918 0.75 FFAR1 (0.51) ALDH1A1NPC1L3MBTL1TDP1MAPK1
SCHEMBL20066494 0.74 FFAR1 (0.37) ALDH1A1L3MBTL1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135818-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2019-05-09 US disclosed
EP-3470415-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135818-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF FGFR1, FGFR3, FGFR4 ALDH1A1 697/4885NPC1 3835/4885L3MBTL1 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.